Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)

Overview of Performance

JMS Co.,Ltd. posted revenue of 32,391 million yen for the cumulative second quarter period, a slight increase of 0.5% Year-over-Year. Price increases for core products and higher sales of certain items contributed, while rising raw material and labor costs weighed on profits. Operating income turned positive to 9 million yen, and ordinary income was negative; interim net loss attributable to owners of parent increased to 262 million yen compared with the prior year. The full-year outlook was revised, with forecasts of revenue 68,000 million yen, operating income 700 million yen, ordinary income 400 million yen, and net income attributable to owners of parent 100 million yen. The dividend is expected to be 8.50 yen at the end of the second quarter and 17.00 yen for the full year.

Segment Trends and Financial Position

The Japan segment saw growth in sales of pharmaceutical preparation, closed infusion systems, and infusion pumps. Conversely, revenue declined due to the discontinuation of certain products and lower sales of dialysis equipment to China. In Singapore, sales of circuits and blood bags for North America were strong, but foreign exchange effects and other factors limited segment profitability. Overall, total assets were 82,922 million yen, equity ratio was 50.5%, current assets were 47,455 million yen, current liabilities were 24,628 million yen, and non-current liabilities were 16,377 million yen.